Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurocrine (NBIX) has provided an update.
Neurocrine Biosciences, Inc. has announced the retirement of its current President and CEO, Kevin C. Gorman, Ph.D., slated for October 11, 2024, while confirming that he will remain on the company’s board. Taking his place, Kyle Gano, Ph.D., with a substantial track record in the company and experience in business development, will become the new President and CEO, also joining the board. This leadership transition comes alongside a change in the company’s bylaws to expand the board size to accommodate the new appointment.
For detailed information about NBIX stock, go to TipRanks’ Stock Analysis page.